Company intelligence / Profile preview

Marathon Pharmaceuticals

Northbrook, Illinois, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Marathon Pharmaceuticals developed Emflaza (deflazacort), a glucocorticoid for treating Duchenne muscular dystrophy. The drug received FDA approval in February 2017, but the company faced significant backlash over its pricing strategy ($89,000 per year compared to $1,000 in other countries). Shortly after approval, Marathon sold the rights to Emflaza to PTC Therapeutics for $140 million plus potential milestone payments and royalties[2][7].

Therapeutic areas: GastroenterologyHematologyRare DiseasesNeurology
Modalities: Small moleculesglucocorticoids
Industry: Biotech

Drug pipeline

4 assets

deflazacort

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

National Organization of Rare Disorders (NORD)

Beyond the preview

Go deeper on Marathon Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marathon Pharmaceuticals.

Explore the full profile